Redwood Pharma carries out a rights issue with the aim of replacing the existing credit facility
August 25, 2019 9:00 pmOn August 25, 2019, the Board of Directors of Redwood Pharma AB (publ) decided to carry out a rights issue... View Article
On August 25, 2019, the Board of Directors of Redwood Pharma AB (publ) decided to carry out a rights issue... View Article
Den 25 augusti 2019 beslutade styrelsen i Redwood Pharma AB (publ) att genomföra en företrädesemission av aktier som vid full... View Article
On August 27, CEO Martin Vidaeus from Redwood Pharma will present at BioStock Live (www.biostock.se) in Stockholm. The presentation will... View Article
Den 27 augusti presenterar VD Martin Vidaeus från Redwood Pharma på BioStock Live (www.biostock.se) i Stockholm. Presentationen hålls på engelska. Program... View Article
Last patient recruited in Redwood Pharma Phase II trial
Redwood Pharma AB (publ) today announces that the last patient has now been included in the company’s ongoing Phase II... View Article
Redwood Pharma AB (publ) meddelar idag att den sista patienten nu har inkluderats i bolagets pågående Fas II-prövning av RP101 och att... View Article
Earlier this week, Redwood Pharma published an update on the Phase II clinical trial of RP101 where the company has... View Article
Pressrelease Tidigare i veckan publicerade Redwood Pharma en uppdatering om den kliniska Fas II-prövningen av RP101 där bolaget nu har... View Article
Update regarding financing and Phase II trial (in Swedish with subtitles)